GT
Elite in Chemosis
Areas of Expertise

Many doctors have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a doctor treats and their level of experience.

Check Dr. Gail L. Torkildsen's experience treating your condition:
About Dr. Gail L. Torkildsen

Gail Torkildsen is an Ophthalmologist in Andover, Massachusetts. Torkildsen has been practicing medicine for over 30 years and is rated as an Elite expert by MediFind in the treatment of Chemosis. She is also highly rated in 7 other conditions, according to our data. Her top areas of expertise are Allergic Conjunctivitis, Giant Papillary Conjunctivitis, Vernal Keratoconjunctivitis, and Conjunctivitis (Pink Eye). She is licensed to treat patients in Massachusetts. Torkildsen is currently accepting new patients.

Her clinical research consists of co-authoring 36 peer reviewed articles and participating in 39 clinical trials in the past 15 years. In particular, she has co-authored 6 articles in the study of Chemosis.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Gail L. Torkildsen it is best to call her office and ask if your insurance is accepted.


Call to see if your plan is accepted.
Locations
138 Haverhill St, Suite 104, Andover, MA 01810
Background & Education
Graduate Institution
University Of Pittsburgh School Of Medicine, 1992
Specialties
Ophthalmology
Licenses
Ophthalmology in MA
Languages Spoken
English
Gender
Female
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


38 Clinical Trials

Single Center, Randomized, Double-Masked Evaluation of the Efficacy of PredAcetate 1% Ophthalmic Suspension Compared to Pred Acetate 0.12% Ophthalmic Suspension, Lot Etab 0.2% Ophthalmic Suspension, and Placebo in a Modified CAC Model
A Phase 2b Study Evaluating the Safety and Efficacy of AR-15512 Ophthalmic Solution for the Treatment of Dry Eye Disease (COMET-1)
A Phase II, Multi-Center, Randomized, Placebo-Controlled, Double-Masked Study of RX-10045 (0.09%) in the Treatment of Dry Eye Disease
A Single-Center, Double-Masked Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia
A Single-Center, Randomized, Controlled Study to Evaluate the Efficacy of Two Investigational OTC Eye Drops in Healthy Adults With Red Eye
Randomized, Controlled, Crossover Study Comparing Tear Production by Nasal Neurostimulation Versus Active Control
Prospective, Open-Label, Randomized, Proof of Concept Study Exploring Application of TrueTear™ for the Treatment of Meibomian Gland Disease
Evaluation of Dexamethasone Phosphate Delivered by Ocular Iontophoresis for the Treatment of Dry Eye in the Controlled Adverse Environment (CAE) Model
A Single-Center, Double-Masked, Randomized, Placebo-Controlled Evaluation of Prednisolone Sodium Phosphate Ophthalmic Solution, 1% Compared to Placebo in a Modified Conjunctival Allergen Challenge (CAC) Model
A Double-Masked, Randomized, Placebo-Controlled Study of Loteprednol Etabonate Ophthalmic Suspension, 0.5% for the Treatment of Dry Eye Used Either TID or QID for a 2 Week Period
A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AC-170 Ophthalmic Solution
Evaluation of Dexamethasone Phosphate Delivered by Ocular Iontophoresis for Treatment of Dry Eye in the Controlled Adverse Environment Model
View 37 Less Clinical Trials -

Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors
Distinguished
Advanced
Advanced